chartexchange

X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire Inc. | Nov 4, 2026 4:15 PM EST

- 4WARD Phase 3 Chronic Neutropenia Trial Expected to Achieve Target Enrollment in Q4 2026 -

Read original article